Skip Navigation LinksHome > April 2012 - Volume 59 - Issue > SPEAKER SCHEDULE*
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/01.qai.0000413721.27409.e4
Speaker Schedule

SPEAKER SCHEDULE*

Free Access
Back to Top | Article Outline

Sunday, October 30, 2011

Special Symposium on HIV Prevention, Care and Treatment from the PEPFAR Program in Africa

Chairs: Alash'le Abimiku and Martine Etienne-Mesubi

10:30 – 10:45—Izukanji Sikazwe, Institute of Human Virology /University of Maryland School of Medicine, AIDSRelief Zambia

Evaluation of AIDSRelief Facilities' Implementation of 2007 HIV Treatment Regimens After Introduction of the New Guidelines—AF1

10:45 – 11:00—Nicaise Ndemi, Institute of Human Virology-Nigeria

Pattern of Drug Resistant Mutations Among Nigerian Patients on PEPFAR NRTINNRTI Regimens—AF2

11:00 – 11:15—Saidu Amed, Federal Ministry of Health, Nigeria

Counseling and Testing and Access-to-Care Needs of Populations Most-at-Risk for HIV in Nigeria—AF3

11:15 – 11:30—Phyllis Kanki, Harvard School of Public Health, Boston, MA

HIV Drug Resistance in Nigeria, a Cost-Effective New Methodology—AF4

11:30 – 11:45—Mary-Ann A. Etiebet, Institute of Human Virology-Nigeria

High HIV-1 Prevalence, Risk Behaviors and Viral Loads Seen in Men Who Have Sex With Men Enrolled in a Community-Based Comprehensive HIV/AIDS Clinic in Nigeria—AF5

11:45 – 12:00—Chuka J. Anude, Division of Epidemiology and Prevention, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD

The HACART Study: Predictors of Immuno-Virologic Outcomes and Immuno-Virologic Discordance Among Adults on HIV Antiretroviral Therapy in Nigeria—AF6

12:00 – 12:30—Lunch

12:30 – 12:45—A. Maghimbi, Institute of Human Virology /University of Maryland School of Medicine, AIDSRelief Tanzania

Early Post – Anti- Retroviral Therapy Associated Mortality: Is It a Significant Problem That is Worthy Exploring? The Experience of AIDS Relief Tanzania—AF7

12:45 – 1:00—Cyprien Baribwira, Institute of Human Virology /University of Maryland School of Medicine, AIDSRelief Rwanda

Mortality Following Initiation of ART in 2 AIDSRelief Supported District Hospitals in Rwanda—AF8

1:00 – 1:15—V. J. Tepper, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD

Relationship Between MEMSTM Adherence Rate, Pill Count and Viral Suppression Among HIV-Infected Children on Antiretroviral Therapy in Nigeria—AF9

1:15 – 1:30—S. Ojoo, Institute of Human Virology /University of Maryland School of Medicine, AIDSRelief Kenya

Viral Response in HIV Infected Children Receiving Antiretroviral Therapy in The AIDSRelief Program in Kenya: A Retrospective Cross-Sectional Survey

1:30 – 1:40—Robert R. Redfield, Institute of Human Virology William Blattner, Institute of Human Virology

Closing Remarks

Back to Top | Article Outline
Track A

Back to Top | Article Outline
New Agents for Treatment of Viral Diseases

Chairs: Robert Redfield and John Bartlett

2:00—Robert Siliciano

Understanding How HAART Works—101

2:20—James Arthos

HIV-1 gp120 Interactions With the Gut Homing Receptor Integrin α4β7 on CD4+ T Cells—103

2:40—David Thomas

New Treatment for Hepatitis C Virus Infection—104

3:00—John Bartlett

New Treatments for HIV Infection—105

3:20—Break – 15 minutes

3:35—Robert Redfield

Targeting CCR5 Density for Treatment and Prevention—106

3:55—Angus Dagleish

The Potential Role of Antibodies to the C5 Domain in gp120 Mitigating Generalized Immune Activation Associated With HIV-1 Infection

4:15—Paolo Lusso

Interleukin-7 As an Immune Reconstitution Agent in HIV-1 Infection: Ex Vivo and in Vivo Protective Effects on CD4+ T Cells—107

4:35—John Moore

Towards Coitally-Independent Microbicides: Studies with Vaginal Rings and Silicone-Based Gel Delivery Systems—108

4:55—Leonid Margolis

HIV-1 Transmission from Semen to the Female Genital Tract and Its Prevention, as Seen in an ex vivo Tissue Model—109

5:30 – 7:30—Welcome Reception, Marriott Hotel

Back to Top | Article Outline

Monday, October 31, 2011

Special Lecture

8:30—Paul Offit

Hard Knocks: Communicating Science to the Public—110

Back to Top | Article Outline
Track B

Back to Top | Article Outline
Mechanisms for Vaccine Protection Against HIV

Chairs: Jose Esparza and William Hall

9:00— Morgane Bomsel

Mucosal Gp41- Virosome Vaccine Protects Rhesus Macaques from Multiple Vaginal Challenges with Heterologous SHIV

9:20—Leo Stamatatos

Interactions Between HIV Env and Germline Versions of bNAbs—111

9:40—George Lewis

Diversity of Specificity and Function Among Human Antibodies to Transitional Epitopes Altered by CD4 Binding to the HIV-1 Env Glycoprotein—112

10:00—Barton Haynes

Protective Antibody Responses in HIV Vaccinees and Infected Subjects

10:20—Break – 15 minutes

10:35—Nelson Michael

Immune Correlates of Infection Risk in the Thai Phase III ALVAC-HIV/AIDSVA-B/E Prime Boost Study—113

10:55—Susan Zolla-Pazner

Role of Vaccine-Induced V2 Antibodies in Protection from HIV Infection of Recipients in the RV144 Clinical Vaccine Trial—114

11:15—David Montefiori

Autologous and Heterologous Neutralizing Antibody Responses in HIV-1 Infection—116

11:35—Dan Barouch

Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenger in Rhesus Monkeys—122

Back to Top | Article Outline
Special Lecture

11:55—Anthony Fauci

Ending the HIV/AIDS Pandemic: A Realistic Goal—117

12:30 – 2:00—Lunch

Back to Top | Article Outline
Special Lecture

2:00—Michel Nussenweig

The Neutralizing Antibody Response to HIV

Back to Top | Article Outline
Track C

Back to Top | Article Outline
Evaluating Candidate HIV Vaccines

Chairs: Gunnel Biberfeld and Arnaldo Caruso

2:30—Jonathan Gershoni

Deep Panning – High Resolution Profiling Antibody Specificities—119

2:50—Peter Kwong

Structural Immunology and Vaccine Development—120

3:10—Norman Letvin

Effect of Activating KIR Copy Number Variation on NK Cell Containment of SIV Replication in Rhesus Monkeys—121

3:30—George Pavlakis

DNA and Protein Vaccination via Electroporation Confers Protection Against Mucosal Challenge with Heterologous SIVsmE660—115

3:50—Marjorie Robert-Guroff

Vaccine-Elicited Antibodies Contribute to Protective Efficacy, Including Mucosal Antibodies, Correlated with Delayed SIV Acquisition—123

4:10—Harriet Robinson

GeoVax HIV/AIDS Vaccine Program, Preclinical and Clinical Studies—124

4:30—Break – 10 minutes

4:40—James Mullins

The Dynamics of Early HIV Infection and a Consequent New Approach to Vaccine Design—125

5:00—Gary Nabel

Broadly Neutralizing HIV Abs: Gains and Losses in Translation—126

Back to Top | Article Outline
Special Lecture

5:20—Nicoli Nattrass

Fighting AIDS Denialism—127

6:00 – 8:00—Poster Reception, Marriott Hotel

Back to Top | Article Outline

Tuesday, November 1, 2011

Special Lecture

8:30—Peter Palese

Toward a Universal Influenza Virus Vaccine—128

Back to Top | Article Outline
Track D

Back to Top | Article Outline
Interactions of HIV and Host Cells

Chairs: Anthony DeVico and Luigi Buonaguro

9:00—Ashley Haase

Live Attenuated Vaccine Induced Mucosal Antibodies and Early Events in the SIV-NHP Model of HIV-1 Transmission to Women—129

9:20—Thomas Hope

Neutralizing and Non-Neutralizing HIV-Specific Antibodies Hinder the Movement of Virus in Fresh Human Cervical Mucus—130

9:40—Eric Hunter

Characteristics of Transmitted Founder Viruses: Impact of Transmitting Partner Genetics—131

10:00—Donald Forthal

Antibodies and Fc Receptors: Their Potential Impact on HIV Infection—132

10:20—Break – 15 minutes

10:35—Mario Stevenson

Factors Influencing HIV-Macrophage Interplay

10:55—Rick Bushman

HIV DNA Integration: Mechanism and Consequences—134

11:15—Paul Bieniasz

Tetherin - Keeping Virions on a Leash—135

11:35—Alain Lafeuillade

A Roadmap Towards HIV Infection Cure—136

11:55—Irvin Chen

Stem Cell Therapy for HIV Disease—137

12:15—Andrea Cerutti

A Novel Innate Pathway for Antibody Diversification and Production—102

12:35 – 2:00—Lunch

Back to Top | Article Outline
Special Lecture

2:00—Diane Griffin

Mechanisms of Virus Clearance from the Nervous System—138

Back to Top | Article Outline
Track E

Back to Top | Article Outline
Immune Mechanisms Controlling Viral Disease

Chairs: Guido Poli and Isaac Witz

2:30—Ed Berger

Epitope Masking Mechanism Within the HIV-1 Env Trimer Analyzed by Functional Subunit Complementation—139

2:50—Guido Silvestri

Antiviral Immune Responses, Chronic Immune Activation, and Pattern of Infected Cells in AIDS Pathogenesis: A Lesson from Non-Human Primate Models—140

3:10—Mario Roederer

The Role of T Memory Stem Cells: Pathogenesis and Vaccines—141

3:30—David Pauza

Cause and Consequence of CD4-Negative T Cell Depletion During HIV Disease—142

3:50—Break – 10 minutes

4:00—Paolo Rossi

Pediatric HIV Infection: Forging a Path Towards Therapeutic Vaccination—143

4:20—Judy Lieberman

The Cytosolic Exonuclease TREX1 Digests HIV Reverse Transcripts to Avoid Triggering an Antiviral Interferon Response in T Cells and Macrophages—144

4:40—Warner Greene

Pyroptosis and HIV-Induced CD4 T Cell Death—145

5:00—Samuel Broder

Therapy Against HIV-1/AIDS: Past, Present, Future

6:30—Institute of Human Virology Lifetime Achievement Awards Reception

Back to Top | Article Outline
Special Speaker

Samuel Broder, M.D., Director, NCI (retired)

Bernadine Healy: The Fundamental Truths of Her Life

7:30 Gala Dinner

Back to Top | Article Outline

Wednesday, November 2, 2011

Track F

Back to Top | Article Outline
Virally-Associated Malignant Diseases

Chairs: William Blattner and Franco Buonaguro

8:30—Genoveffa Franchini

Retooling the Macaque Model to Evaluate the Relative Efficacy of HIV Vaccine Candidates—154

8:50—Bassam Badran

CD4+CD25+CD127low Regulatory T Cells: MicroRNA Signature and Effect of Valproate on microRNA and FOXP3 Expression Levels in CD4+CD25- T Cells—155

9:10—Clement Adebamowo

Developing AIDS Associated Cancer Research in Africa—147

9:30—Robert Yarchoan

Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Related Multicentric Castleman's Disease (MCD) and Inflammatory Cytokine Syndrome (KICS): Pathogenesis and Treatment—148

9:50—Anna Linda Zignego

Hepatitis C Virus (HCV)-Related Lymphoproliferative Disorders—149

10:10—Jim Goedert

Update on Malignancies Among People with HIV/AIDS—150

10:30—Break 15 minutes

10:45—Sam Mbulaiteye

Virally Associated Malignancies in the HIV Era—151

11:05—Ali Bazarbachi

Can We Cure HTLV-I Associated Adult T Eell Leukemia Lymphoma?—152

11:25—K. T. Jeang

Transformation of Human Cells by HTLV-1 Tax—153

11:45—Patrick Moore

What Happens When Your Viral Flora Gives You Cancer?—156

Back to Top | Article Outline
Special Lecture

12:05—Jay A. Berzofsky

Strategies for Anti-Cancer Immunotherapy Using Vaccines and Blockade of Negative Regulation—157

© 2012 Lippincott Williams & Wilkins, Inc.

Login